McKeage Kate
Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Paediatr Drugs. 2016 Feb;18(1):75-81. doi: 10.1007/s40272-015-0160-2.
The intranasal formulation of zolmitriptan, a selective serotonin 5-HT1B/1D agonist, was recently approved by the US Food and Drug Administration for the treatment of acute migraine in pediatric patients 12 years of age or older. This article summarizes the efficacy and tolerability of zolmitriptan (Zomig(®)) nasal spray (NS) in acute migraine in this patient group. Zolmitriptan NS 5 mg was more effective in relieving headache pain than placebo in two double-blind studies in pediatric patients 12-17 years of age with acute migraine. Furthermore, zolmitriptan NS 2.5 and 5 mg effectively relieved photophobia and phonophobia, and was associated with a faster return to normal daily activities than placebo. Zolmitriptan NS is rapidly absorbed from the nasal mucosa and is associated with a fast onset of action, with one study showing a significant difference versus placebo with regard to headache response 15 min after administration. In both trials, zolmitriptan NS was generally well tolerated, with no serious adverse events. In conclusion, zolmitriptan NS provides rapid, effective and generally well tolerated treatment of acute migraine in pediatric patients 12 years of age or older and may be of particular benefit for those with nausea or not easily able to swallow tablets.
佐米曲普坦是一种选择性5-羟色胺5-HT1B/1D激动剂，其鼻内制剂最近获得美国食品药品监督管理局批准，用于治疗12岁及以上儿科患者的急性偏头痛。本文总结了佐米曲普坦（佐米格（®））鼻喷雾剂（NS）在该患者群体急性偏头痛治疗中的疗效和耐受性。在两项针对12 - 17岁急性偏头痛儿科患者的双盲研究中，5毫克佐米曲普坦鼻喷雾剂在缓解头痛疼痛方面比安慰剂更有效。此外，2.5毫克和5毫克佐米曲普坦鼻喷雾剂能有效缓解畏光和畏声症状，且与比安慰剂更快恢复正常日常活动相关。佐米曲普坦鼻喷雾剂从鼻黏膜迅速吸收，起效快，一项研究显示给药后15分钟时在头痛反应方面与安慰剂有显著差异。在两项试验中，佐米曲普坦鼻喷雾剂总体耐受性良好，无严重不良事件。总之，佐米曲普坦鼻喷雾剂为12岁及以上儿科患者的急性偏头痛提供了快速、有效且总体耐受性良好的治疗，对于那些有恶心症状或不易吞服片剂的患者可能特别有益。
